Canada Markets closed

Qiagen N.V. (QIA.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
42.48-0.16 (-0.38%)
At close: 06:35PM CEST
Full screen
Previous Close42.64
Bid0.00 x 48300
Ask0.00 x 51100
Day's Range42.35 - 43.10
52 Week Range39.94 - 49.37
Avg. Volume425,914
Market Cap9.822B
Beta (5Y Monthly)0.38
PE Ratio (TTM)33.48
EPS (TTM)1.27
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 25, 2017
1y Target Est47.90
  • Business Wire

    QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

    VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.

  • Zacks

    QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact

    QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.

  • Business Wire

    QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

    VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).